The Essentials in Hemodialysis

1. Front Matter

   Pages 1-8

   PDF

2. Preface

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 9-9

3. Indications for Regular Dialysis Treatment

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 11-12

4. The Consequences of Loss of Renal Function the Mechanisms of «Uremic Toxicity»

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 13-18

5. Basic Principles of Hemodialysis

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 19-27

6. Hemodialysis Equipment

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 28-35

7. Vascular Access

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 36-39

8. Organization of Dialysis Treatment

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 40-47

9. Performance and Follow-Up of Regular Dialysis Treatement

   • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

   Pages 48-69

10. Clinical Problems in Chronic Hemodialysis Patients

    • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

    Pages 70-86

11. Living with Hemodialysis

    • Paul Jungers, Johanna Zingraff, Nguyen K. Man, Tilman Drueke

    Pages 87-89

12. Back Matter

    Pages 90-102

    PDF

At the end of 1976 there were 34,215 people with end-stage renal disease alive on dialysis and transplantation within the registry centers of the European Dialysis and Transplant Association (14:4, 1977). From July, 1973, when the American Government began to fund dialysis, the estimated number of dialysis patients in the United States has risen from 5,000 plus to over 35,000. Jfwe add other regions, such as Canada, Australasia and Latin America, it is safe to say that as this is written, over 100,000 people are living on dialysis. The u.s. Social Security System, Veterans Administration, Medicaid and State Agencies are now paying out over one billion dollars annually to support patients on dialysis in the U. S.A. Cobe, Redy, Travenol, Dow Cordis, Drake Willock, Gambro, Asahi, Erica and a host of other company names have become household words in many households throughout the world. I cite these factors not out of a pretense at precision or a passion for phenomenology, but simply to indicate that dialysis has become lore than this century's therapeutic miracle. (Perhaps the first treatable fatal chronic, terminal, medical disease I). It has also become big business! As such, it has perhaps become too important to be left solely in the hands of medical specialists, such as nephrologists.

• child
• dialysis
• diseases
• fat
• hemodialysis
• kidney
• lead
• metabolism
• monitoring
• organizations
• quality
• quality of life
• toxicity
• transplantation
• water

• Faculty of Medicine Necker-Enfants Malades, Necker Hospital, Paris, France

  Paul Jungers

• INSERM U 25, Necker Hospital, Paris, France

  Johanna Zingraff, Nguyen K. Man

• Faculty of Medicine Necker, Necker Hospital, Paris, France

  Tilman Drueke

Policies and ethics